On October 20, 2025, Lexeo Therapeutics, a clinical-stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, announced the closing of its previously announced underwritten public offering and concurrent private placement, for total gross proceeds to Lexeo of approximately $153.8 million, before deducting underwriting discounts and commissions and other expenses. Wilson Sonsini Goodrich & Rosati represented Lexeo in the transaction.

In the public offering, Lexeo sold 17,968,750 shares of its common stock at $8.00 per share, which includes the full exercise of the underwriters’ option to purchase 2,343,750 shares of Lexeo’s common stock. Concurrently, Lexeo sold prefunded warrants to purchase 1,250,015 shares of its common stock to Balyasny Asset Management at a price of $7.9999 per pre-funded warrant, in a private placement exempt from the registration requirements of the Securities Act of 1933.

The Wilson Sonsini team that represented Lexeo in the transaction included Megan Baier, David Sharon, Carole Rosenberg, Mesha Rivers, and Sophia Kunthara.

For more information, please see Lexeo’s news release.